Juyoung Shin, PhD, is a Professor at the College of Pharmacy, Sungkyunkwan University, where she serves as the Chair of the Department of Biohealth Regulatory Science. She received her BS in Pharmacy, MPH in Health Policy and Management, and PhD in Pharmacoepidemiology from Seoul National University.
Her research focuses on pharmacoepidemiology, drug safety, and the use of large-scale healthcare data to evaluate the effectiveness and safety of medications. She has extensive expertise in real-world data analysis, particularly in assessing drug interactions and adverse events across diverse populations.
Dr. Shin has published over 200 peer-reviewed articles in leading international journals, including BMJ, Gut, and JAMA Pediatrics. Her work has contributed to advancing the understanding of medication safety, including studies on cardiovascular risks associated with ADHD treatments and bleeding risks linked to antidepressant use.
She previously worked as a postdoctoral researcher at McGill University and served as the Head of the DUR Information Team at the Korea Institute of Drug Safety and Risk Management. She is actively engaged in academic and policy communities as an associate editor of international journals and a member of professional societies and government advisory committees.
Her contributions have been recognized with several awards, including the Distinguished Pharmaceutical Scientist Award and the Young Epidemiologist Award.

Min-young Lim is a Clinical Operations Director at GSK Korea with over 24 years of experience in the pharmaceutical industry. She began her career at GSK Biologicals and later held leadership roles at Novartis Vaccines & Diagnostics, building strong expertise in clinical trial execution, quality, and regulatory compliance.

Since rejoining GSK, she has led Vx clinical operations as Country Clinical Operations Head for Vaccines Korea. Currently, she oversees clinical research delivery across all therapeutic areas in Korea, driving innovation through new technologies and operational excellence.

Min-young also plays an active role in shaping Korea’s clinical research environment. She served as Chair of the Clinical Trial Review Subcommittee under the MFDS CHORUS initiative (2023?2024), contributing to the improvement of clinical trial review processes and guideline revisions. Additionally, she leads regulatory initiatives within the KRPIA R&D Committee and collaborates closely with regulatory authorities to enhance clinical trial efficiency and competitiveness in Korea.

JinKyoung Kwon is a Manager in Regulatory Affairs at IQVIA Korea with over 10 years of experience in clinical research and regulatory affairs. She specializes in regulatory strategy, IND submissions, and clinical trial approvals in Korea, supporting a wide range of development programs from early-phase studies to multinational clinical trials. In her current role, she leads regulatory activities and site activation for global clinical studies, working closely with pharmaceutical and biotechnology companies. Her expertise includes Korean clinical trial regulations, regulatory submissions, study start-up strategy, and supporting multinational pharmaceutical and biotechnology companies in clinical development.

SuhIm has built her career across clinical operations, regulatory affairs, and CMC, gaining broad experience in the end-to-end conduct of clinical trials in both global and local pharmaceutical settings. She began her career in clinical operations at Celltrion, where she supported and later managed global clinical studies across multiple therapeutic areas, contributing to study start-up, site management, IND preparation, and cross-functional project execution. She subsequently joined Roche, where her role expanded into local regulatory leadership, including IND submissions and amendments, regulatory consultation, and collaboration with global teams on Korea-specific regulatory strategy.
In her current role at MSD Korea, SuhIm serves as a Clinical Operations Manager with responsibilities spanning IND leadership, local regulatory management, start-up oversight, and CMC strategy for clinical studies in Korea. She has led internal efforts to build and strengthen in-house CMC capabilities, developed training programs to cultivate regulatory expertise within the organization, and serves as a subject matter expert for regulatory information management processes.
SuhIm has also played an active leadership role in CHORUS, a pharmaceutical industry?MFDS consultative working group, where she has led discussions and coordinated cross-company perspectives on key regulatory topics. Through these efforts, she has contributed to practical regulatory discussions related to IND review requirements and guideline updates, helping improve the clinical trial environment in Korea. This combination of operational, regulatory, and policy-facing experience provides the foundation for her perspective on current regulatory issues in clinical research.
She holds a Bachelor’s degree in Life Science from Chung-Ang University and a Master’s degree in Industrial Pharmaceutical Sciences from Yonsei University.

Heewon brings ~13 years of bi-cultural clinical research experience spanning local and global environments. At Eli Lilly, she leads clinical trial allocation, site selection, and enrollment strategy for Lilly’s neuroscience pipeline in South Korea, while also contributing to CMH and oncology studies. Much of her work is driven by a single question: who gets left out of clinical studies, and why? Tackling the structural barriers to patient access has become a defining thread of her career, one she continues to pursue through new models of trial design and investigator engagement.

Dr. Gisoo Kang is a Vice President and Partner at BNH Investment, LLC, a premier venture capital firm dedicated to driving innovation in the Bio/Healthcare sector. Since joining the firm in 2018, Dr. Kang has established herself as a key investment professional, leading the discovery, rigorous evaluation, and strategic post-investment management of high-potential startups within the bio-healthcare sector. Capitalizing on her extensive global network with multinational pharmaceutical companies and international investors, she specializes in introducing promising Korean biotech companies to the global stage and actively accelerating their international expansion and cross-border partnerships.

Dr. Kang’s strength as a venture capitalist is backed by years of strategic corporate experience. Prior to BNH Investment, she served as a Senior Manager at CJ Corporation. There, she spearheaded corporate development and open innovation initiatives, analyzing global trends in healthcare and bio-based materials to propose strategic investments and global partnership opportunities.

Her investment acumen is further enhanced by a distinguished background in scientific research, allowing her to evaluate biological assets with unique technical precision. Dr. Kang previously conducted research as a Postdoctoral Fellow at the National Institutes of Health (NIH) in the United States, focusing on rare lung diseases and cellular mechanisms.

Dr. Kang holds a Ph.D. in Environmental Health Sciences (Environmental Toxicology) from New York University and a Bachelor of Science from Seoul National University. Blending deep scientific expertise, a robust global network, and extensive venture capital experience, she continues to play a pivotal role in accelerating the next generation of healthcare breakthroughs.

Hyun-Ki Kim is Managing Director at Stonebridge Ventures, where he leads bio and healthcare investments. Since joining in 2018, he has helped build the firm’s life sciences practice, focusing on technically differentiated companies with the potential to compete globally and deliver meaningful impact for patients.

He has been actively investing in and supporting emerging innovators such as Adel, Nex-I, and Ingenia Therapeutics, reflecting his conviction in science-driven companies that can create long-term value. His approach combines scientific expertise, global business development experience, and venture investing insight, shaped by his prior roles as a senior researcher at Dong-A Pharmaceutical, in global BD at Dong-A ST, and as a Boston-based investor at NS Investment.

He holds a B.S. in Biotechnology from Sungkyunkwan University and an M.S. in Biochemical Engineering from Seoul National University.

Dr. Yeojung Moon is a passionate investor at IMM Investment with various early-to-late stage investment experiences in bio and healthcare. As the first MD into the venture capital industry, she has guided various early-stage bio and healthcare startups to establish and grow their business into global scale. Leveraging her clinical and research experience at Yonsei Severance Hospital as an OBGYN doctor, she has been recognized as an early-detector of differentiated technology and hands-on supporter to her portfolio partners. Her track record is accentuated by her distinctive contribution to Lunit (KOSDAQ:A32813) as a multi-time investor and a board member(aka Lunit’s Mom) to realize their mission to “Conquer Cancer through AI”

She holds a board seat of Hanwha Investment & Securities Co., Ltd.(KOSPI: 003530) and is a selected member of Presidential committee of Korea’s 4th industrial revolution.

Prior to joining IMM, Dr. Moon led Bio investment division at InterVest. She was also an assistant professor at Yonsei Severance Hospital. Yeojung holds PhD in Neuroscience and MD from Yonsei University.

2019- Senior managing director, IMM Investment Corp.
2016-2018 Director, Intervest Co.
2004-2016 Clinical Professor, Severance Hospital, OBGYN
2014 Yonsei University, School of Medical Science, Ph.D
2004 Yonsei university, School of Medicine, MD